Literature DB >> 29309879

Anti-nociceptive Role of CXCL1 in a Murine Model of Peripheral Nerve Injury-induced Neuropathic Pain.

Ling Cao1, Jennifer T Malon2.   

Abstract

Both spinal cord infiltrating CD4+ T lymphocytes and microglial CD40 contribute to the maintenance of neuropathic pain-like behaviors induced by spinal nerve L5 transection (L5Tx), a murine model of neuropathic pain. Here, we sought to investigate the involvement of multiple chemokines in microglial CD40-mediated and CD4+ T lymphocytes-mediated L5Tx-induced sensory hypersensitivity. Spinal cord chemokine expression in CD4 knockout (KO), CD40 KO, and wild type (WT) BALB/c mice was determined at the protein level via multiplex assays and at the RNA level via quantitative real-time PCR. In WT mice, L5Tx induced significant increases in CCL2, CCL3, and CCL5 expression (protein and RNA) up to day 21 post-L5Tx, while CD4 KO mice displayed blunted, predominantly non-significant, responses in these chemokines at protein levels post-L5Tx. L5Tx also induced increased expression of these chemokines in CD40 KO mice; however, the overall protein levels of these chemokines were significantly lower than those in WT mice. Further, L5Tx induced a significant increase in CXCL1 at the protein level and in CXCR2 at RNA level only in CD40 KO mice. Intrathecal administration of CXCL1 in WT mice significantly reduced L5Tx-induced mechanical hypersensitivity. CD40 KO mice also displayed higher levels of Ly6G (neutrophil marker) RNA expression in the lumbar spinal cord post-L5Tx. Altogether, our data suggest that CD4+ T lymphocytes and microglial CD40 mediate their pro-nociceptive effects in part by promoting selected chemokine responses, and more importantly, CXCL1 can play an anti-nociceptive role in peripheral nerve injury-induced neuropathic pain, which is possibly mediated by infiltrating neutrophils.
Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD4; CD40; CXCL1; chemokines; neuropathic pain; spinal nerve L5 transection

Mesh:

Substances:

Year:  2018        PMID: 29309879      PMCID: PMC5827969          DOI: 10.1016/j.neuroscience.2017.12.048

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  34 in total

Review 1.  Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation.

Authors:  Céline Callewaere; Ghazal Banisadr; William Rostène; Stéphane Mélik Parsadaniantz
Journal:  J Mol Endocrinol       Date:  2007-03       Impact factor: 5.098

2.  Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain.

Authors:  Ling Cao; Christopher D Palmer; Jennifer T Malon; Joyce A De Leo
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

3.  Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model.

Authors:  Jiin-Tarng Liou; Hui-Bih Yuan; Chih-Chieh Mao; Ying-Shu Lai; Yuan-Ji Day
Journal:  Pain       Date:  2012-04-10       Impact factor: 6.961

4.  Role of interleukin-4, the chemokine CCL3 and its receptor CCR5 in neuropathic pain.

Authors:  Shiyu Sun; Dan Chen; Fuqing Lin; Minghui Chen; Hongli Yu; Lengchen Hou; Cheng Li
Journal:  Mol Immunol       Date:  2016-08-11       Impact factor: 4.407

5.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

6.  Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model.

Authors:  Jiin-Tarng Liou; Chih-Chieh Mao; Daniel Ching-Wah Sum; Fu-Chao Liu; Ying-Shu Lai; Jui-Chin Li; Yuan-Ji Day
Journal:  J Pain       Date:  2012-11-23       Impact factor: 5.820

7.  Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2.

Authors:  Catherine Abbadie; Jill A Lindia; Anne Marie Cumiskey; Larry B Peterson; John S Mudgett; Ellen K Bayne; Julie A DeMartino; D Euan MacIntyre; Michael J Forrest
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

Review 8.  Leukocyte-derived opioid peptides and inhibition of pain.

Authors:  Halina Machelska; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

9.  Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia.

Authors:  Ryutaro Ochi-ishi; Kenichiro Nagata; Tomoyuki Inoue; Hidetoshi Tozaki-Saitoh; Makoto Tsuda; Kazuhide Inoue
Journal:  Mol Pain       Date:  2014-08-15       Impact factor: 3.395

10.  Differential lumbar spinal cord responses among wild type, CD4 knockout, and CD40 knockout mice in spinal nerve L5 transection-induced neuropathic pain.

Authors:  Ling Cao; Holly Beaulac; Adriana Eurich
Journal:  Mol Pain       Date:  2012-12-18       Impact factor: 3.395

View more
  11 in total

1.  Multiplex Assessment of Serum Chemokines CCL2, CCL5, CXCL1, CXCL10, and CXCL13 Following Traumatic Brain Injury.

Authors:  Yuwen Chen; Ying Wang; Jian Xu; Tingting Hou; Jing Zhu; Yingzi Jiang; Liying Sun; Chunling Huang; Lulu Sun; Su Liu
Journal:  Inflammation       Date:  2022-08-15       Impact factor: 4.657

Review 2.  A role for pericytes in chronic pain?

Authors:  Alexandra M Durrant; Matthew N Swift; Nicholas Beazley-Long
Journal:  Curr Opin Support Palliat Care       Date:  2018-06       Impact factor: 2.302

3.  Contribution of CD137L to Sensory Hypersensitivity in a Murine Model of Neuropathic Pain.

Authors:  Alexa A Wakley; Reno Leeming; Jenn Malon; Taxiarhia J Arabatzis; Woon Yuen Koh; Ling Cao
Journal:  eNeuro       Date:  2018-11-08

4.  Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury.

Authors:  Anna Piotrowska; Ewelina Rojewska; Katarzyna Pawlik; Grzegorz Kreiner; Agata Ciechanowska; Wioletta Makuch; Irena Nalepa; Joanna Mika
Journal:  Front Immunol       Date:  2019-09-26       Impact factor: 7.561

5.  Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy.

Authors:  Dan Ziegler; Alexander Strom; Gidon J Bönhof; Julia M Kannenberg; Margit Heier; Wolfgang Rathmann; Annette Peters; Christina Meisinger; Michael Roden; Barbara Thorand; Christian Herder
Journal:  BMJ Open Diabetes Res Care       Date:  2019-11-27

6.  Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis.

Authors:  Xiu-Xiu Liu; Lin Yang; Ling-Xiao Shao; Yang He; Gang Wu; Yu-Huan Bao; Nan-Nan Lu; Dong-Mei Gong; Ya-Ping Lu; Tian-Tian Cui; Ning-He Sun; Dan-Yang Chen; Wei-Xing Shi; Kohji Fukunaga; Hong-Shan Chen; Zhong Chen; Feng Han; Ying-Mei Lu
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

7.  A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis.

Authors:  Maria Tredicine; Chiara Camponeschi; Davide Pirolli; Matteo Lucchini; Mariagrazia Valentini; Maria Concetta Geloso; Massimiliano Mirabella; Marco Fidaleo; Benedetta Righino; Camilla Moliterni; Ezio Giorda; Mario Rende; Maria Cristina De Rosa; Maria Foti; Gabriela Constantin; Francesco Ria; Gabriele Di Sante
Journal:  iScience       Date:  2022-01-11

8.  Protocatechuic acid as an inhibitor of the JNK/CXCL1/CXCR2 pathway relieves neuropathic pain in CCI rats.

Authors:  Hong-Xia Chang; Yue-Feng Zhao
Journal:  Bosn J Basic Med Sci       Date:  2022-04-01       Impact factor: 3.363

9.  The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing-Remitting Multiple Sclerosis Mouse Model.

Authors:  Gabriele Di Sante; Susanna Amadio; Beatrice Sampaolese; Maria Elisabetta Clementi; Mariagrazia Valentini; Cinzia Volonté; Patrizia Casalbore; Francesco Ria; Fabrizio Michetti
Journal:  Cells       Date:  2020-03-18       Impact factor: 6.600

10.  S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis.

Authors:  Chiara Camponeschi; Maria De Carluccio; Susanna Amadio; Maria Elisabetta Clementi; Beatrice Sampaolese; Cinzia Volonté; Maria Tredicine; Vincenzo Romano Spica; Rosa Di Liddo; Francesco Ria; Fabrizio Michetti; Gabriele Di Sante
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.